Increased frequency of CYP2C19 loss-of-function alleles in clopidogrel-treated patients with recurrent cerebral ischemia.
Crista MinderhoudLeila S OttenPieter H E HilkensMarcel P H van den BroekAnkie M HarmszePublished in: British journal of clinical pharmacology (2022)
In this clopidogrel-treated population with recurrent cerebral ischaemia, the frequency of CYP2C19 LoF alleles was significantly higher than in reference groups, especially in early recurrent events. This study adds to the growing body of evidence that genotype-guided antiplatelet therapy could improve patient outcomes.